Trials that use: Covariate adjustment
5,848 results
- Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy: Complete Statistical AnalysisIndependent statistical analysis of Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Tolerability Study of SHP626 in Overweight and Obese Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of SHP626 in Overweight and Obese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device: Complete Statistical AnalysisIndependent statistical analysis of Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01708213).
- Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD: Complete Statistical AnalysisIndependent statistical analysis of Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD: primary endpoint results, effect estimate with…
- Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ Vaccine in Healthy Vietnamese Children: Complete Statistical AnalysisIndependent statistical analysis of Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR: Complete Statistical AnalysisIndependent statistical analysis of Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to
- Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.: Complete Statistical AnalysisIndependent statistical analysis of Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma: Complete Statistical AnalysisIndependent statistical analysis of Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval,…
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety of Vitamin D Supplementation in Older Persons: Complete Statistical AnalysisIndependent statistical analysis of Safety of Vitamin D Supplementation in Older Persons: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00681590).
- Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety Study of Cosmetic Tissue Augmentation in People of Color: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of Cosmetic Tissue Augmentation in People of Color: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147172).
- Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age: primary endpoint results, effect…
- Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008): Complete Statistical AnalysisIndependent statistical analysis of Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01678807).
- Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy: Complete Statistical AnalysisIndependent statistical analysis of Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying…
- Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors: Complete Statistical AnalysisIndependent statistical analysis of Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali:…
- Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): primary endpoint results, effect estimate with confidence…
- Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02068690).
- Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04138043).
- Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran: primary endpoint results, effect…
- Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer: primary endpoint results, effect estimate with confidence…
- Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801): Complete Statistical AnalysisIndependent statistical analysis of Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00541775).
- Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…